CTOs on the Move

Microline Surgical

www.microlinesurgical.com

 
Microline Surgical develops and manufactures high precision open and laparoscopic surgical instruments. Microline`s laparoscopic reposable instruments provide a cost-effective and eco-friendly solution for today`s OR. The MiFusion product line offers a broad spectrum of open and laparoscopic instruments used to seal and divide tissue utilizing proprietary Thermal Fusion technology.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Horizon Behavioral Health

Behavioral health, Recovery, drug, rehabilitation, mental illness, depression, Appomattox, Appomattox County, Virginia, Central Virginia, alcoholism, Alcohol

Global Pharmaceutical Sourcing

Global Pharmaceutical Sourcing is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fougera Pharmaceuticals

Fougera Pharmaceuticals is a Melville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medaus Pharmacy

Medaus Pharmacy is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia